menu
    • menu
    [{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Chord Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"1","companyTruncated":"Chord Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Chord Therapeutics \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Chord Therapeutics

    Menu

    Chord Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Chord Therapeutics

    Switzerland arrow
    euroPLX 87
    Not Confirmed

    Chord Therapeutics

    Switzerland arrow
    euroPLX 87
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cladribine

    Therapeutic Area : Immunology

    Study Phase : Preclinical

    Sponsor : Merck & Co

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

    Details : The company entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a company focused on rare neuroinflammatory diseases. Acquisition provides opportunity to develop cladribine in Myasthenia Gravis and Neuromyelitis Optica ...

    Product Name : Mavenclad

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    December 20, 2021

    Lead Product(s) : Cladribine

    Therapeutic Area : Immunology

    Highest Development Status : Preclinical

    Sponsor : Merck & Co

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Chord Therapeutics

    Switzerland arrow
    Organic Process R&D
    Not Confirmed

    Chord Therapeutics

    Switzerland arrow
    Organic Process R&D
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cladribine

    Therapeutic Area : Neurology

    Study Phase : Undisclosed

    Sponsor : Omega Funds

    Deal Size : $16.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Chord Therapeutics Launches with USD 16 million Series A Financing

    Details : The financing will allow the company to progress CRD1 through Phase 2 proof of concept clinical development. The potential of CRD1 to address unmet medical needs in rare autoimmune disorders was identified by Chord Therapeutics‘ founder, Dr. Arthur Roa...

    Product Name : CRD1

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    October 13, 2020

    Lead Product(s) : Cladribine

    Therapeutic Area : Neurology

    Highest Development Status : Undisclosed

    Sponsor : Omega Funds

    Deal Size : $16.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth